[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335699-105":59,"doc-detail-335699-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-biological-roles-and-clinical-applications-of-the-pi3kakt-pathway-in-targeted-therapy-resistance-in-her2-positive-breast-cancer-a-comprehensive-review-review","The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review - Review","","Epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is highly invasive and malignant, with poor prognosis driven by resistance to HER2-targeted therapy and a strong tendency toward metastasis. This review addresses mechanisms of resistance and treatment development focused on the PI3K/AKT signaling pathway, frequently altered across cancers and central to proliferation and drug resistance. It integrates current knowledge on pathway alterations, biological functions, and clinical applications, while considering safety, regulation, ethics, and differential treatment responses across patient populations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-biological-roles-and-clinical-applications-of-the-pi3kakt-pathway-in-targeted-therapy-resistance-in-her2-positive-breast-cancer-a-comprehensive-review-review/335699/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-biological-roles-and-clinical-applications-of-the-pi3kakt-pathway-in-targeted-therapy-resistance-in-her2-positive-breast-cancer-a-comprehensive-review-review/335699.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HER2-positive breast cancer difficult to treat?","Question",{"text":112,"@type":113},"HER2+ BC is highly malignant and invasive, and resistance to HER2-targeted therapy contributes to poor prognosis and frequent metastasis tendency.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does the PI3K/AKT pathway play in drug resistance?",{"text":117,"@type":113},"The PI3K/AKT pathway is frequently altered in cancers and controls cellular proliferation while supporting complex signaling interactions that contribute to drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What HER2-targeted treatment options are highlighted across therapy lines?",{"text":121,"@type":113},"The review summarizes first-line monoclonal antibodies (trastuzumab, pertuzumab), second-line antibody–drug conjugates (T-DM1, T-Dxd), and later therapies including margetuximab and TKIs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335699,1790196545,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Review  \nThe Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review  \nHanyi Zhong †, Ziling Zhou †, Han Wang, Ruo Wang , Kunwei Shen, Renhong Huang * and Zheng Wang *  \nCitation: Zhong, H.; Zhou, Z.; Wang, H.; Wang, R.; Shen, K.; Huang, R.; Wang, Z. The Biological Roles and Clinical Applications of the  \nPI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review. Int. J. Mol. Sci. 2024, 25, 13376. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms252413376  \nAcademic Editor: Andrea Nicolini  \nReceived: 18 November 2024  \nRevised: 6 December 2024  \nAccepted: 9 December 2024  \nPublished: 13 December 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; [zhonghanyi2010@163.com](zhonghanyi2010@163.com) (H.Z.);  \n[yugizzl@hotmail.com](yugizzl@hotmail.com) (Z.Z.); [wanghan8844@163.com](wanghan8844@163.com) (H.W.); [wangruo@sjtu.edu.cn](wangruo@sjtu.edu.cn) (R.W.);  \n[kwshen@medmail.com.cn](kwshen@medmail.com.cn) (K.S.)  \n* [Correspondence: hrh1217@sjtu.edu.cn](Correspondence: hrh1217@sjtu.edu.cn) (R.H.); [zhengwang@shsmu.edu.cn](zhengwang@shsmu.edu.cn) (Z.W.)† These authors contributed equally to this work.  \nAbstract: Epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is a highly invasive and malignant type of tumor. Due to its resistance to HER2-targeted therapy, HER2+ BC has a poor prognosis and a tendency for metastasis. Understanding the mechanisms underlying this resistance and developing effective treatments for HER2+ BC are major research challenges. Thephosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway, which is frequently altered in cancers, plays a critical role in cellular proliferation and drug resistance. This signaling pathway activates various downstream pathways and exhibits complex interactions with other signaling networks. Given the significance of the PI3K/AKT pathway in HER2+ BC, several targeted drugs are currently in development. Multiple drugs have entered clinical trials or gained market approval, bringing new hope for HER2+ BC therapy. However, new drugs and therapies raise concerns related to safety, regulation, and ethics. Populations of different races and disease statuses exhibit varying responses to treatments. Therefore, in this review, we summarize current knowledge on the alteration and biological roles of the PI3K/AKT pathway, as well as its clinical applications and perspectives, providing new insights for advancing targeted therapies in HER2+ BC.  \nKeywords: HER2-positive breast cancer; targeted therapy; PI3K/AKT pathway; drug resistance  \n1. Introduction  \nBreast cancer (BC) is one of the most prevalent cancers worldwide, representing the second leading cause of cancer-related mortality among women globally [1] . Clinically, breast cancer is categorized into the three following major subtypes based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2, also known as ERBB2): hormone receptor-positive breast cancer (HR+ BC), HER2-positive breast cancer (HER2+ BC), and triple-negative breast cancer (TNBC) [2] . Approximately 20% to 25% of breast cancer cases exhibit HER2 overexpression, which is characterized by a higher propensity to display metastasis, resistance to chemotherapy and hormonal therapy, shortened survival, and poor prognosis.  \nHER2-targeted the","cbCainjk6aNagJeu","https://ap.wps.com/l/cbCainjk6aNagJeu","pdf",2383034,39,"English","# Introduction\n## Breast cancer subtypes and HER2-targeted therapy overview\n# Targeted therapies for HER2-positive disease\n## First-line monoclonal antibodies (trastuzumab, pertuzumab)\n## Second-line antibody–drug conjugates (T-DM1, T-Dxd)\n## Third-line interventions and later therapies (margetuximab, TKIs)\n# Clinical applications and perspectives","[{\"question\":\"Why is HER2-positive breast cancer difficult to treat?\",\"answer\":\"HER2+ BC is highly malignant and invasive, and resistance to HER2-targeted therapy contributes to poor prognosis and frequent metastasis tendency.\"},{\"question\":\"What role does the PI3K/AKT pathway play in drug resistance?\",\"answer\":\"The PI3K/AKT pathway is frequently altered in cancers and controls cellular proliferation while supporting complex signaling interactions that contribute to drug resistance.\"},{\"question\":\"What HER2-targeted treatment options are highlighted across therapy lines?\",\"answer\":\"The review summarizes first-line monoclonal antibodies (trastuzumab, pertuzumab), second-line antibody–drug conjugates (T-DM1, T-Dxd), and later therapies including margetuximab and TKIs.\"}]","The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review - Review | PDF",1790011983,98]